CARCINOGENESIS, published by Oxford University Press, is a premier journal dedicated to the nuanced field of cancer research. With an ISSN of 0143-3334 and an E-ISSN of 1460-2180, this esteemed journal plays a crucial role in disseminating high-quality research findings since its inception in 1980, making it a cornerstone in the exploration of carcinogenic processes. As of 2023, it stands out with a commendable Q2 ranking in Cancer Research and a Q1 ranking in Medicine (miscellaneous), reflecting its significant impact in advancing knowledge in these vital areas. Supported by a strong Scopus ranking, specifically holding the 61st position out of 230 in Biochemistry, Genetics, and Molecular Biology within Cancer Research, CARCINOGENESIS provides researchers, healthcare professionals, and students access to peer-reviewed articles that cover a broad spectrum of topics related to cancer etiology, prevention, and treatment. Although it is not an open-access journal, its commitment to excellence ensures that every published article contributes meaningfully to the global fight against cancer, making it an essential resource for those engaged in cutting-edge cancer research.

CURRENT GENETICS is a prestigious journal published by SPRINGER, dedicated to advancing the field of genetics through the dissemination of high-quality research. With a notable impact factor and ranking in the Q2 category for both Genetics and Medicine (miscellaneous) as of 2023, it firmly establishes itself as a significant resource for the academic community. The journal’s comprehensive scope explores the latest findings in genetic research, along with accompanying interdisciplinary studies, providing a platform for researchers to share innovative ideas and methodologies. ISSN: 0172-8083, E-ISSN: 1432-0983, stands testament to its commitment to scholarly excellence. While Open Access options are not currently available, CURRENT GENETICS remains accessible to a broad audience, promoting a rich exchange of knowledge that supports the vast and evolving discipline of genetics. Since its inception in 1979 and through its converged years till 2024, this journal has played a crucial role in confronting scientific challenges and promoting advancements in genomic medicine and molecular biology. As such, it is an essential read for researchers, professionals, and students keen to remain at the forefront of genetic research.

The EUROPEAN JOURNAL OF HUMAN GENETICS, published by SpringerNature, stands as a preeminent platform in the field of genetics and clinical genetics. Established in 1993, this prestigious journal, with an ISSN of 1018-4813 and an E-ISSN of 1476-5438, has consistently maintained its position in the Q1 quartile for both Genetics and Clinical Genetics categories as of 2023, reflecting its significant contributions to the field. Its impact is further underscored by its impressive Scopus rankings, placing it in the 92nd percentile among clinical genetics journals. The journal aims to disseminate cutting-edge research, case studies, and reviews that advance our understanding of human genetics, promoting collaboration and innovation among researchers, professionals, and students alike. While it does not currently offer open access, the journal provides substantial value through its rigorous peer review process and commitment to quality. As it continues to shape the future of genetic research through 2024 and beyond, the EUROPEAN JOURNAL OF HUMAN GENETICS remains an essential resource for those dedicated to exploring the complexities of human heredity.

HEREDITAS, published by BMC, is a distinguished Open Access journal that has been a pivotal platform for the dissemination of cutting-edge research in the fields of genetics and biomedical sciences since its inception in 1920. With an impressive history spanning over a century, HEREDITAS has maintained a strong commitment to providing unrestricted access to high-quality scientific articles, ensuring that researchers and practitioners worldwide can share their findings and insights. This journal, which operates from its headquarters in the United Kingdom, is positioned within the Q3 quartile for Genetics and Q2 for miscellaneous Medicine categories according to the 2023 metrics, reflecting its significant yet evolving role in the academic landscape. Researchers are drawn to HEREDITAS not only for its legacy but also for its impact factor and contributions to the broader understanding of hereditary processes. The journal serves as an essential resource for students, scholars, and professionals who are keen on advancing the knowledge frontiers in genetics and related disciplines. With its open access policy implemented since 2005, HEREDITAS not only champions the principle of knowledge dissemination but also plays a crucial role in fostering collaborative research efforts across the globe.

Application of Clinical Genetics is a premier open-access journal published by Dove Medical Press Ltd., dedicated to advancing the field of clinical genetics since its inception in 2008. Based in New Zealand, this journal has established itself as a significant resource for researchers, clinicians, and students alike, contributing to the body of knowledge in both genetic medicine and clinical applications. With an impact factor reflecting its contributions to the field, the journal holds positions in the Q2 and Q3 quartiles of the 2023 Genetics categories, showcasing its relevance and scientific merit. Furthermore, it ranks #43 out of 99 in Clinical Genetics and #153 out of 347 in Biochemistry, Genetics, and Molecular Biology, indicating robust performance amongst its peers. The journal’s broad scope, encompassing various aspects of clinical genetics, ensures that it remains at the forefront of critical discussions, innovative research, and applications essential for the progression of personalized medicine. Researchers and professionals are encouraged to explore its openly accessible content that fosters collaboration and the sharing of knowledge in this dynamic and rapidly evolving field.

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

MUTAGENESIS, published by Oxford University Press, is a leading journal in the fields of genetics, toxicology, and health, dedicated to advancing our understanding of mutagenic processes and their implications for human health. With an ISSN of 0267-8357 and an E-ISSN of 1464-3804, this journal has been at the forefront of mutagenesis research since its inception in 1986 and will continue to publish cutting-edge studies until 2024. Holding an impressive position in the academic community, MUTAGENESIS is ranked Q2 in Genetics, Q2 in Clinical Genetics, Q2 in Health, Toxicology, and Mutagenesis, and Q1 in Toxicology, reflecting its commitment to high-quality scholarly work. The journal enjoys a robust global readership, with significant rankings in various Scopus categories, including top positions in Environmental Science and Clinical Genetics, ensuring that it remains a vital resource for researchers, professionals, and students alike. While access to its articles is not completely open, MUTAGENESIS provides valuable insights that fuel innovative research and drive forward the understanding of genetic risks and toxicological assessments.

GENETICS IN MEDICINE, published by Elsevier Science Inc, stands as a premier journal in the realms of clinical genetics and medicine. With an impressive impact factor and ranked #3 out of 99 in the category of Genetics (clinical), alongside a 97th percentile ranking in the Scopus database, this journal is recognized for its outstanding contribution to the field. Established in 1998, it aims to disseminate innovative research and clinical advancements bridging genetics and medical practice, making it essential reading for researchers, healthcare professionals, and students alike. Although not an open-access journal, GENETICS IN MEDICINE provides valuable insights into genetics that drive the future of personalized medicine and patient care. With a commitment to excellence, the journal continuously explores the evolving landscape of genetic research to foster the understanding and application of genetic principles in medical contexts.

GENES & GENETIC SYSTEMS, an esteemed journal published by the Genetics Society of Japan, serves as a vital platform for the dissemination of innovative research within the fields of genetics, molecular biology, and medicine. Established in 1996 and based in Mishima, Shizuoka, Japan, this journal has actively contributed to the academic community, fostering collaboration and knowledge sharing among researchers and professionals. The journal’s impact can be seen through its category quartiles, which reflect its position in Genetics, Molecular Biology, and Medicine, and while it currently ranks in Q4 in Genetics and Q3 in Medicine (miscellaneous), it is poised for growth as it continues to publish pivotal studies. With a commitment to open access, GENES & GENETIC SYSTEMS ensures that research findings are freely accessible to the global scientific community, promoting a more inclusive approach to knowledge distribution. This journal is essential for students, researchers, and professionals seeking to stay informed of advancements in genetic research and its implications for the broader field of medicine.

Gene Reports is a prominent academic journal published by Elsevier that focuses on the rapidly evolving field of genetics. Launched in 2015, this journal serves as a pivotal platform for the dissemination of cutting-edge research, bridging the gap between basic and applied genetics studies. Although it currently holds a Q4 ranking in the Genetics category and stands at the 248th position out of 347 in Scopus rankings, its potential for growth is significant given the increasing interest in genetic research across various disciplines. With an E-ISSN of 2452-0144, Gene Reports aims to provide open access to original research articles, reviews, and short communications that advance the collective understanding of genetic mechanisms and their applications. As a publication that continues to shape the future of genetics, it is an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in this crucial field.